Bisphosphonate Therapy Breast Cancer

  bisphosphonate therapy breast cancer: Adjuvant Therapy for Breast Cancer Monica Castiglione, Martine J. Piccart, 2009-07-11 Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable.
  bisphosphonate therapy breast cancer: Adjuvant Therapy of Breast Cancer I. Craig Henderson, 2012-11-05 The results of randomized trials evaluating the use of early or adjuvant systemic treatment for patients with resectable breast cancer provide an eloquent rebuttal to those who would argue that we have made no progress in the treatment of cancer. Many of the tumors that we have been most successful in curing with chemotherapy and other newer forms of treatment are relatively uncommon. In contrast, breast cancer continues to be the single most common malignancy among women in the western world, is increasingly a cause of death throughout Asia and Third-World countries, and remains one of the most substantial causes of cancer mortality world wide. The use of mammography as a means of early detection has been shown to reduce breast cancer mortality by 25-35% among those popu lations in which it is utilized. The use of adjuvant systemic treatment in appropriate patients provides a similar (and additional) reduction in breast cancer mortality. Few subjects have been so systematically studied in the history of medicine, and it seems fair to conclude that the value to adjuvant systemic therapy in prolonging the lives of women with breast cancer is more firmly supported by empirical evidence than even the more conventional or primary treatments using various combinations ofsurgery and radiotherapy.
  bisphosphonate therapy breast cancer: Prevention of Bone Metastases Markus Joerger, Michael Gnant, 2012-01-05 Bone metastases continue to be a major cause of morbidity in cancer patients, but improved understanding of the biology of bone metastases has led to the identification of drugs that are of potential value in not only their treatment but also their prevention. This book, written by recognized experts in the field, provides a detailed overview of current knowledge on this subject. One important focus of the book is the efficacy of bisphosphonates in preventing bone metastases in patients with breast, lung, and prostate cancer and disease progression in cases of multiple myeloma. The combined use of bisphosphonates and cytostatics is also discussed, with a report on first clinical data. Further topics addressed include the significance of the bone microenvironment, special issues in the elderly patient, the use of bone turnover markers, and initial findings obtained with denosumab.
  bisphosphonate therapy breast cancer: Bisphosphonates in Bone Disease Herbert Fleisch, 2000-04-18 This book is an essential handbook on bisphosphonates, the most widely used new class of drugs for osteoporosis therapy. It reviews basic physiology in addition to the indications and adverse reactions of these drugs. Bisphosphonates in Bone Disease, 4E, discusses the compounds' chemistry, mechanisms of action, and animal toxicology before presenting a clinical picture of the diseases treated by bisphosphonates. The book provides a table listing the trade names of the commercially available bisphosphonates, registered indications, and the available forms for various countries. The revised Fourth Edition contains approximately 50% new material, including information on all of the latest drugs. * The revised fourth edition contains approximately 50% new material * Includes information on all the latest drugs
  bisphosphonate therapy breast cancer: Hypercalcemia of Malignancy Friedhelm Raue, 2012-12-06 Hypercalcemia is the most common life-threatening metabolic disorder associated with cancer. The pathophysiological, epidemiological and clinical aspects of hypercalcemia of malignancy are presented in this issue, with a focus on the recently discovered humoral factor responsible for the development of hypercalcemia. With a better understanding of the pathophysiology of this condition and the development of new potent drugs, capable of inhibiting bone resorption, especially bisphosphonates, the clinician will be more successful in correcting hypercalcemia in the great majority of patients.
  bisphosphonate therapy breast cancer: Medication-Related Osteonecrosis of the Jaws Sven Otto, 2014-11-27 Osteonecrosis of the jaws is a well-known side-effect of antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous administrations of denosumab, a monoclonal antibody. Less frequently it may also be observed in patients with osteoporosis who are being treated with these antiresorptive drugs This textbook provides detailed, up-to-date information on all aspects of medication-related osteonecrosis of the jaws, including clinical features, pathogenesis, treatment options, and preventive measures. It also explains safe prevention and treatment strategies for patients receiving antiresorptive drugs who require extractions, implant insertions, and other dento-alveolar surgeries. This book will be of major interest for medical and dental students, dentists, and oral and maxillofacial surgeons as well as osteologists and oncologists.
  bisphosphonate therapy breast cancer: Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide Agency for Health Care Research and Quality (U.S.), 2013-02-21 This User’s Guide is a resource for investigators and stakeholders who develop and review observational comparative effectiveness research protocols. It explains how to (1) identify key considerations and best practices for research design; (2) build a protocol based on these standards and best practices; and (3) judge the adequacy and completeness of a protocol. Eleven chapters cover all aspects of research design, including: developing study objectives, defining and refining study questions, addressing the heterogeneity of treatment effect, characterizing exposure, selecting a comparator, defining and measuring outcomes, and identifying optimal data sources. Checklists of guidance and key considerations for protocols are provided at the end of each chapter. The User’s Guide was created by researchers affiliated with AHRQ’s Effective Health Care Program, particularly those who participated in AHRQ’s DEcIDE (Developing Evidence to Inform Decisions About Effectiveness) program. Chapters were subject to multiple internal and external independent reviews. More more information, please consult the Agency website: www.effectivehealthcare.ahrq.gov)
  bisphosphonate therapy breast cancer: Bisphosphonates and Osteonecrosis of the Jaw, Volume 1218 John P. Bilezikian, John T. Grbic, 2011-03-14 This volume presents manuscripts stemming from the conference entitled 'Bisphosphonates & Osteonecrosis of the Jaw,' held May 19, 2007 at the New York Academy of Sciences
  bisphosphonate therapy breast cancer: Bone Health and Osteoporosis United States Public Health Service, Surgeon General of the United States, 2004-12 This first-ever Surgeon General's Report on bone health and osteoporosis illustrates the large burden that bone disease places on our Nation and its citizens. Like other chronic diseases that disproportionately affect the elderly, the prevalence of bone disease and fractures is projected to increase markedly as the population ages. If these predictions come true, bone disease and fractures will have a tremendous negative impact on the future well-being of Americans. But as this report makes clear, they need not come true: by working together we can change the picture of aging in America. Osteoporosis, fractures, and other chronic diseases no longer should be thought of as an inevitable part of growing old. By focusing on prevention and lifestyle changes, including physical activity and nutrition, as well as early diagnosis and appropriate treatment, Americans can avoid much of the damaging impact of bone disease and other chronic diseases. This Surgeon General's Report brings together for the first time the scientific evidence related to the prevention, assessment, diagnosis, and treatment of bone disease. More importantly, it provides a framework for moving forward. The report will be another effective tool in educating Americans about how they can promote bone health throughout their lives. This first-ever Surgeon General's Report on bone health and osteoporosis provides much needed information on bone health, an often overlooked aspect of physical health. This report follows in the tradition of previous Surgeon Generals' reports by identifying the relevant scientific data, rigorously evaluating and summarizing the evidence, and determining conclusions.
  bisphosphonate therapy breast cancer: Breast Cancer Adnan Aydiner, Abdullah Igci, Atilla Soran, 2019-01-31 This book is a practical guide to the management of patients with breast malignancies. It serves as a quick reference book that gives the most up-to-date routine practical management strategies of breast cancer. Written and edited by leading experts, this handbook focuses on the application of conventional and novel treatment strategies to the care of patients with malignant breast disease and all stages of breast cancer. The chapters provide evidence-based treatment strategies for all patient subsets. Surgical, radiation, and medical treatment options are all discussed for each stage of breast cancer. It also includes the definitions of statistical terminologies and their usage in clinical practice and research. This is a comprehensive yet concise resource for residents, fellows, and early-career practitioners.
  bisphosphonate therapy breast cancer: Breast Cancer Management for Surgeons Lynda Wyld, Christos Markopoulos, Marjut Leidenius, Elżbieta Senkus-Konefka, 2017-11-29 This textbook provides a comprehensive overview of the state of the art knowledge of breast cancer management for the modern breast surgeon. It covers all aspects of multidisciplinary care including primary breast and axillary surgery, reconstruction and oncoplastic techniques, external beam radiotherapy and newer techniques such as tomotherapy, intraoperative radiotherapy and brachytherapy. In addition, systemic therapies including chemotherapy, the latest biological targeted therapies and endocrine therapies are covered. Readers can find out about other important aspects of breast cancer such as genetics, screening, imaging and long-term health among others. Chapters take the reader through the basics up to the highest levels of knowledge in an easy to understand format with management algorithms to aid clinical care, generous referencing of the best literature and figures and photographs to illustrate each section. Published with the official approval of the European Society of Surgical Oncology (ESSO) and the European Society of Breast Cancer Specialists (EUSOMA), the book is written by a panel of recognised leaders in the field and is an indispensable guide for the practicing breast specialist and senior specialists in training, wishing to update their knowledge with the latest trends or polish off their training before accreditation.
  bisphosphonate therapy breast cancer: Skeletal Metastases Charles Samuel Bernard Galasko, 1986
  bisphosphonate therapy breast cancer: Drug-induced Ocular Side Effects and Drug Interactions Frederick T. Fraunfelder, 1982
  bisphosphonate therapy breast cancer: Diagnosing and Treating Adult Cancers and Associated Impairments National Academies Of Sciences Engineeri, National Academies of Sciences Engineering and Medicine, Health And Medicine Division, Board On Health Care Services, Committee on Diagnosing and Treating Adult Cancers, 2021-11-10 Cancer is the second leading cause of death among adults in the United States after heart disease. However, improvements in cancer treatment and earlier detection are leading to growing numbers of cancer survivors. As the number of cancer survivors grows, there is increased interest in how cancer and its treatments may affect a person's ability to work, whether the person has maintained employment throughout the treatment or is returning to work at a previous, current, or new place of employment. Cancer-related impairments and resulting functional limitations may or may not lead to disability as defined by the U.S. Social Security Administration (SSA), however, adults surviving cancer who are unable to work because of cancer-related impairments and functional limitations may apply for disability benefits from SSA. At the request of SSA, Diagnosing and Treating Adult Cancers and Associated Impairments provides background information on breast cancer, lung cancer, and selected other cancers to assist SSA in its review of the listing of impairments for disability assessments. This report addresses several specific topics, including determining the latest standards of care as well as new technologies for understanding disease processes, treatment modalities, and the effect of cancer on a person's health and functioning, in order to inform SSA's evaluation of disability claims for adults with cancer.
  bisphosphonate therapy breast cancer: Infusion Therapy Alaa Abd-Elsayed, 2019-05-23 There is a significant gap in current knowledge about infusion therapy for treating different pain, headache and psychiatric conditions. Infusion therapy is now a common practice but there is considerable variation in how the therapy is implemented in different centers which can be both dangerous, if high doses are given, or ineffective, if low doses are given. This book provides a practical guide to infusion therapy for clinicians on how to safely and effectively perform this kind of therapy. Chapters cover the pharmacology of each medication and evidence in literature regarding indications, contraindications and doses. A recommended algorithm is provided for patient selection, doses, infusion technique/doses and appropriate monitoring. Infusion Therapy is the first comprehensive, clinical guide to this practice and is an invaluable resource for clinicians in anesthesia, pain medicine, internal medicine and palliative care. It will also be of interest to researchers and pharmacologists who would like to find out how clinicians use infusions.
  bisphosphonate therapy breast cancer: Elsevier's 2022 Intravenous Medications - E-Book Shelly Rainforth Collins, 2021-04-16 Find the essential information you need to safely administer more than 400 intravenous drugs! For more than 45 years, Gahart’s Intravenous Medications: A Handbook for Nurses and Health Professionals has been a trusted resource for comprehensive drug coverage, unparalleled accuracy, and an intuitive quick-access format. In addition to updated drug interactions, precautions, alerts, and patient teaching instructions for all existing IV drugs, the 2022 edition includes approximately 10 new monographs of the most recent IV drugs to be approved by the FDA. Administering intravenous drugs is a critical task — inaccurate or out-of-date information is not an option. Known as the #1 IV drug handbook on the market, and with its history of impeccable accuracy, Gahart’s annual publication gives you the extra confidence and guidance you need to safely and effectively treat patients. Monographs on more than 400 IV drugs offer an impressive breadth of coverage that goes well beyond any comparable drug reference. Updated annual publication prevents you from referencing outdated information. Additional drug monographs are provided on the companion Evolve website. 45-year history of impeccable accuracy reinforces the importance of safe IV drug administration. Perfect depth of information equips you with everything that is needed for safe administration of IV drugs — nothing more, nothing less. Proven, clinically optimized format keeps all dosage information for each drug on either a single page or a two-page spread to prevent hand contamination by having to turn a page. Highlighted Black Box Warnings and relevant content make locating critical information fast and easy. Special circumstances in blue-screened text call attention to important circumstances that may not warrant Black Box Warnings. Life-stage dosage variances are highlighted for geriatric, pediatric, infant, and neonatal patients. Dilution and dosage charts within monographs provide quick access to essential clinical information. Convenient, alphabetical format organizes all drug monographs by generic name, allowing you to find any drug in seconds. NEW! Drug monographs for newly approved drugs by the FDA provide you with the most current drug information. Updates on drug interactions, precautions, alerts, and more have been made throughout the guide to reflect all changes to existing medications.
  bisphosphonate therapy breast cancer: Antiresorptive Drug-Related Osteonecrosis of the Jaw (ARONJ) - A Guide to Research Kenneth E. Fleisher, Risto Kontio, Sven Otto, 2016-09-16 A collaboration between some of the leading international experts in the field, AOCMF proudly presents Antiresorptive Drug-related Osteonecrosis of the Jaw (ARONJ)-a Guide to Research, which unravels the many biologic processes and risk factors associated with this debilitating condition. With its unknown pathophysiology, lack of established management regimens, and because of the millions of patients currently taking antiresorptive agents, this important book on ARONJ has been produced to provide the latest in contemporary evidence and insight. The book's key features include: Detailed analysis of the historical definitions, classifications, and clinical features of ARONJ Review of the risk factors and treatment options currently available, and why the jaw bone is predominantly affected Discussion on the use of large and small animals in modelling. With dozens of clinical images to help illustrate the impact of this condition on real patients, Antiresorptive Drug-related Osteonecrosis of the Jaw (ARONJ)-a Guide to Research is an excellent resource for anyone involved or interested in this important medical field.
  bisphosphonate therapy breast cancer: Cancer Chemotherapy and Biotherapy Bruce A. Chabner, Dan L. Longo, 2011-12-07 Updated to include the newest drugs and those currently in development, this Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents—their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations. This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised. A companion website includes the fully searchable text and an image bank.
  bisphosphonate therapy breast cancer: Glucocorticoid-induced Osteoporosis Andrea Giustina, Alberto Angeli, Ernesto Canalis, 2002 Osteoporosis is one of the most clinically relevant disabling chronic disease encountered in clinical practice. A common cause of osteoporosis is glucocorticoid excess, as glucocorticoids may increase bone resorption, inhibit bone formation, have indirect actions on bone by decreasing intestinal calcium absorption and induce hypercalciuria. This book presents a comprehensive overview of the effects of glucocorticoids on bone metabolism and structure and on the diagnosis and treatment of glucocorticoid-induced osteoporosis. It aims at providing updated information on the pathogenesis, diagnosis and treatment of this often dramatic complication of glucocorticoid excess. Being one of the few publications completely devoted to glucocorticoid-induced osteoporosis it will heighten the awareness of specialists who prescribe glucocorticoids of the clinical relevance of this treatment complication. 'Glucocorticoid-Induced Osteoporosis' is addressed to clinical experts as well as to general practitioners who will both benefit from the comprehensive and integrative view of the management of patients exposed to glucocorticoids.
  bisphosphonate therapy breast cancer: Surgical Oncology M Asif Chaudry, Marc C. Winslet, 2009-07-23 An indispensable source of accessible information in both the acute and out-patient setting, Surgical Oncology is a practical reference for surgeons who actively manage cancer patients from initial presentation and diagnosis to investigation and staging, operative management, post-operative care, long term surveillance and palliation.
  bisphosphonate therapy breast cancer: Myeloma Bone Disease G. David Roodman, 2010-04-28 This book presents the forefront in the science and clinical management of myeloma bone disease. Coverage begins with sections on clinical presentation, imaging, and biochemical markers and goes on to discuss radiation, surgical, and medical therapies.
  bisphosphonate therapy breast cancer: Osteoporosis in Clinical Practice Piet Geusens, 2012-12-06 A concise review of the current knowledge of osteoporosis, aimed at the busy pratitioner who is increasingly involved in the management of osteoporosis and who wants accurate and practical answers to questions that arise in daily clinical practice. All the major aspects are covered including diagnosis, fractures, prevention and treatment. Each chapter has been written by a recognised expert in the field to provide readers with the most up-to-date and authoritative knowledge on each of the topics discussed, making this an invaluable source of reference.
  bisphosphonate therapy breast cancer: Oxford Textbook of Endocrinology and Diabetes John A.H. Wass, Paul M. Stewart, 2011-07-28 Now in its second edition, the Oxford Textbook of Endocrinology and Diabetes is a fully comprehensive, evidence-based, and highly-valued reference work combining basic science with clinical guidance, and providing first rate advice on diagnosis and treatment.
  bisphosphonate therapy breast cancer: Metronomic Chemotherapy Guido Bocci, Giulio Francia, 2014-09-04 This book analyzes all aspects of metronomic chemotherapy, a new approach involving low-dose, long-term, and frequently administered therapy that has preclinical and clinical activity in various tumors. After an opening section on the pharmacological bases of metronomic chemotherapy, including its antiangiogenic effects and impact on immunity, preclinical studies on various classes of drug are discussed. Clinical applications of metronomic chemotherapy in a wide variety of tumors are then addressed in detail, with description of the results of all published studies. The clinical pharmacology of metronomic chemotherapy is also considered in depth, encompassing pharmacokinetics, pharmacogenetics, pharmacoeconomics, and adverse drug reactions. The book closes by describing the role of this therapy in the veterinarian clinic.
  bisphosphonate therapy breast cancer: Endocrine and Metabolic Late Effects in Cancer Survivors Francesco Felicetti (Oncologist), Enrico Brignardello, Hanneke M. van Santen, 2021-11 This book analyzes in detail all aspects related to endocrine and metabolic late effects observed in patients treated for cancer, both in childhood and adulthood. The chapters focusing on the possible pathogenic mechanisms of late effects (i.e., premature aging and chronic inflammation) and on bone health in cancer survivors are particularly interesting and innovative. The volume also deals with hypothalamic-pituitary, thyroid and gonadal disorders, including infertility and how to prevent it. Finally, the relationship between metabolic alterations and cardiovascular diseases in cancer survivors is addressed. Thanks to advances in cancer treatment and supportive care, the five-year survival rate of cancer patients is constantly increasing. However, this undisputable success of medicine has a flip side: the late adverse effects of anticancer therapies. Pediatric oncologists were the first to cope with late complications of treatments, but today also adult oncologists and onco-hematologists recognize the relevance of this issue. Even though late effects observed in cancer survivors can affect any organ or system, endocrine and metabolic dysfunctions are the most frequently reported. Endocrine complications rarely influence life expectancy of cancer survivors, but they can significantly impact morbidity and quality of life. Among endocrine adverse effects, severe hypothalamic damage may be considered the most harmful in survivors, leading to morbid obesity, propensity to metabolic syndrome and cardiovascular disease. This book aims to disseminate the knowledge about endocrine and metabolic adverse effects of cancer therapies and about survivorship care. Since the number of cancer survivors is steadily growing in the general population, this publication is intended not only for endocrinologists but also for oncologists, onco-hematologists, internists, pediatric specialists in those areas and general practitioners, with the aim to better counsel and monitor cancer survivors.
  bisphosphonate therapy breast cancer: Endocrinology S.S. Nussey, S.A. Whitehead, 2001-06-15 Traditionally, endocrinology textbooks have been either short notes or multi-author, multi-volume monster, all of which present clinical material last and often only briefly. Endocrinology is different and used real cases to lead readers into the text and then describes the biochemistry, physiology, and anatomy they need to understand the case. The
  bisphosphonate therapy breast cancer: Supportive Care in Respiratory Disease Sam H. Ahmedzai, David R. Baldwin, David C. Currow, 2012-01-26 The second edition of this popular title in the Supportive Care series focuses on the aetiology, diagnosis and management of respiratory diseases, emphasising symptoms, quality of life and psychosocial support. The underlying theme of the book is the application of modern research-based knowledge, in a humane way, for those with advancing disease.
  bisphosphonate therapy breast cancer: Principles of Bone Biology John P. Bilezikian, Lawrence G. Raisz, T. John Martin, 2008-09-29 Principles of Bone Biology provides the most comprehensive, authoritative reference on the study of bone biology and related diseases. It is the essential resource for anyone involved in the study of bone biology. Bone research in recent years has generated enormous attention, mainly because of the broad public health implications of osteoporosis and related bone disorders. - Provides a one-stop shop. There is no need to search through many research journals or books to glean the information one wants...it is all in one source written by the experts in the field - The essential resource for anyone involved in the study of bones and bone diseases - Takes the reader from the basic elements of fundamental research to the most sophisticated concepts in therapeutics - Readers can easily search and locate information quickly as it will be online with this new edition
  bisphosphonate therapy breast cancer: Textbook of Bone Metastases Claude Jasmin, 2005-03-11 The epidemiological and clinical importance of bone metastases has long been recognised. For example, the incidence of bone metastases in breast and prostate cancers is 70%, whereas it is only 30 to 40% in metastatic lung cancer. In clinical terms, bone metastases have substantial negative effects on the patient's quality of life. Bone metastases have generally received insufficient attention because of the difficulty in quantifying them, which has left them outside the scope of therapeutic trials The justification for a textbook on the subject of bone metastases is the quite remarkable progress made recently in the understanding of the molecular and cellular mechanisms involved in osteogenesis and osteolysis and their development for therapeutic purposes. The treatment of malignant hypercalcaemia has also been revolutionised by the use of bisphosphonates. The Textbook of Bone Metastases presents a broad approach to recent progress in all fields related to bone metastases, ranging from epidemiology to the pathophysiology of bone metastases and therapeutics.. This book provides a better understanding of recent advances and, more importantly, will give clinicians all the information needed to help them in the clinical and therapeutic management of patients with bone metastases.
  bisphosphonate therapy breast cancer: Breast Cancer Management and Molecular Medicine Martine J. Piccart, William C. Wood, Chie-Mien Hung, Lawrence J. Solin, Fatima Cardoso, 2007-05-31 Tailoring treatment for individual breast cancers is no longer a dream and is now the main goal for current research. This book gives an overview of the most recent techniques, agents and approaches for breast cancer and the individualization of treatment. Particular attention is given to organ-specific tailored approaches, specific populations, patients’ preferences and rehabilitation. Contributions from experts focus on the biomedical research behind the transfer of molecular biology knowledge into the clinical management of patients. This has led to increased survival as well as improved quality of life. The book gives an overview of the latest achievements in breast cancer and their use in clinical practice.
  bisphosphonate therapy breast cancer: World Health Organization Guidelines on the Pharmacological Treatment of Persisting Pain in Children with Medical Illnesses World Health Organization, 2012 These guidelines have been developed to support countries to relieve pain in their paediatric populations. These guidelines address persisting pain in children caused by conditions such as cancer, HIV/AIDS, sickle-cell disease, burns, trauma, and phantom limb pain. Recommendations -- developed following a careful and transparent appraisal of available evidence -- are presented for the pharmacological treatment of mild, moderate and severe pain. The guidelines include chapters on the various systems used to classify pain and on the evaluation of pain, which reviews the available tools for routine pain measurement in children. Provision of sustainable pain relief within health care systems is covered in a separate chapter. Since morphine and other opioid analgesics -- required for the relief of moderate-to-severe pain in children -- are listed under the 1961 UN Single Convention on Narcotic Drugs, the new guidelines include an annex explaining the Convention's requirements for the handling and procurement of opioid analgesics for the relief of pain.
  bisphosphonate therapy breast cancer: Breast Cancer Antoinette R. Tan, MD, MHSc, 2010-12-16 Breast Cancer: Breast cancer is second only to lung cancer as the leading cancer cause of death in women. In 2010 207,000 women will be diagnosed with breast cancer and over 39,000 are expected to die from breast cancer. Nevertheless, ongoing research and recent advances in both diagnostic and therapeutic modalities continue to make breast cancer management a rapidly evolving area in which the practitioner will want to be fully updated on current developments. Breast Cancer offers a comprehensive and in-depth review of the current literature of breast cancer. Chapters examine risk factors and prevention strategies, trends and developments in imaging, surgical management, radiotherapy advances, adjuvant endocrine and chemotherapies, targeted metastatic therapy, and the role of bisphosphonates and novel bone agents in breast cancer. With this volume the oncology practitioner will have a full and current overview of all significant current trends in this important area of oncology. About the Series: Emerging Cancer Therapeutics is an invited review publication providing a through analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence, current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging. Features of Emerging Cancer Therapeutics include: Editorial board of nationally recognized experts across the spectrum of Cancer Therapeutics In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer Therapeutics Issues edited by an authority in specific subject area Focuses on major topics in Cancer Therapeutics with in-depth articles covering advances in clinical and translational research developments, as well as clinical applications and experience Emphasizes multidisciplinary approaches to research and practice
  bisphosphonate therapy breast cancer: Metastatic Spinal Cord Compression National Collaborating Centre for Cancer (Great Britain), 2008 It is difficult to know what the true incidence of metastatic spinal cord compression (MSCC) is in England and Wales because the cases are not systematically recorded. However, evidence from an audit carried out in Scotland between 1997 and 1999 and from a published study from Ontario, Canada, suggests that the incidence may be up to 80 cases per million population per year. This would mean around 4000 cases per year in England and Wales or more than 100 cases per cancer network per year. The Clinical Resource and Audit Group (CRAG) audit clearly showed that there were significant delays from the time when patients first developed symptoms until hospital doctors and general practitioners recognised the possibility of spinal cord compression and made the appropriate referral. The median times from the onset of back pain and nerve root pain to referral were 3 months and 9 weeks respectively. As a result, 48% of patients were unable to walk at the time of diagnosis and of these the majority (67%) had recovered no function at 1 month. Of those walking unaided at the time of diagnosis (34%), 81% were able to walk (either alone or with aid) at 1 month. The ability to walk at diagnosis was also significantly related to overall survival. At present, relatively few patients with malignant spinal cord compression in the UK receive surgery for the condition. But research evidence suggests that early surgery may be more effective than radiotherapy in a selected subset of patients.
  bisphosphonate therapy breast cancer: Bisphosphonates in Clinical Oncology Beat Thürlimann, 2012-12-06 This book provides a clinically oriented overview on the patho-physiological background and the use of bisphosphonates in oncology. The clinical development of pamidronate to treat tumor-induced hypercalcemia and malignant osteolytic bone disease is demonstrated, as well as the results of pivotal studies. New important findings on how to best use pamidronate in certain indications are given and put in perspective. The author discusses patient management guidelines as well as pharmaco-economic aspects important for the readers.
  bisphosphonate therapy breast cancer: Trends in Breast Cancer Research Andrew P. Yao, 2005 Breast cancer is a malignant tumour that has developed from cells of the breast. A malignant tumour is a group of cancer cells that may invade surrounding tissues or spread (metastasize) to distant areas of the body. The disease occurs almost entirely in women, but men can get it as well. The main types of breast cancer are ductal carcinoma in situ, invasive ductal carcinoma, lobular carcinoma in situ, invasive lobular carcinoma, medullary carcinoma, and Paget's disease of the nipple. About 1 of 8 women will get it in her lifetime. This new book presents state-of-the-art research in this fast-moving field.
  bisphosphonate therapy breast cancer: Journal of the National Cancer Institute , 2014
  bisphosphonate therapy breast cancer: Breast Cancer Survivorship Alistair Ring, Marina Parton, 2016-12-01 This book discusses the impact on women of the diagnosis and treatment of early breast cancer. Readers will learn about the risks of breast cancer recurrence and interventions to reduce these, such as endocrine therapy and bisphosphonate therapy, as well as the role of lifestyle factors such as diet and exercise. The long-term effects of treatment on fertility, the heart and other systems are discussed, as well the psychological burden for women who are increasingly likely to be cured from their cancer. Each chapter provides background and a practical guide in the management of women after the initial phase of diagnosis and treatment. Authored by a multidisciplinary team this book provides all the relevant expertise as well as different perspectives, providing a holistic picture of early breast cancer consequences. From oncologists to general practitioners as well as specialist nurses, gynaecologists, psychologists and other healthcare professionals involved in the long-term care of women with breast cancer, this book provides a timely and indispensable guide to practitioners caring for early breast cancer survivors.
  bisphosphonate therapy breast cancer: Cancer Nursing Connie Yarbro, Debra Wujcik, Barbara Holmes Gobel, 2011 A new and revised version of this best-selling reference! For over eighteen years, best-selling Cancer Nursing: Principles and Practice has provided oncology nurses with the latest information on new trends in the rapidly changing science of oncology. Now, in its Seventh Edition, Cancer Nursing has been completely revised and updated to reflect key new developments. New topics covered include targeted therapy, hypersensitivity reactions, mucositis, and family and caregiver issues. With 27 new chapters featuring insights from key authors, the Seventh Edition is a must-have resource for every oncology nurse.
  bisphosphonate therapy breast cancer: Breast Cancer John K. Erban, MD, Barbara L. Smith, MD, Phd, Alphonse G. Taghian, MD, PhD, 2009-12-17 Breast Cancer: Over the course of the last decade, the treatment of breast cancer has evolved quite rapidly. New scientific and clinical advances have modified the standard of care and led to improved patient outcomes. At the same time, the treatment of breast cancer has become increasingly complex, requiring the comprehensive review and assessment of multiple issues, genetics, radiology, surgery, reconstruction, fertility radiation, chemotherapy, and more. As a result the harmony and open communication between these specialties facilitated by a multidisciplinary team approach are crucial in providing the best care to patients and ensuring successful treatment. Breast Cancer: A Multidisciplinary Approach to Diagnosis and Management, written by a multidisciplinary team of authors representing a range of disciplines, is a valuable resource for physicians, fellows, nurses, physician assistants, physical therapists, and all health care providers involved in the treatment of breast cancer. Breast Cancer: A Multidisciplinary Approach to Diagnosis and Management summarizes the state-of-the-art issues related to the treatment of breast cancer and describes an approach for optimal multidisciplinary care for women who have been diagnosed with breast cancer or who are at higher risk to develop breast cancer. About the Series The Current Multidisciplinary Oncology series edited by Charles R. Thomas consolidates and integrates the varied aspects of multidisciplinary care for major topics in oncology, including breast, lung, prostrate, head and neck and more. The volumes in the Current Multidisciplinary Oncology series represent all related topic areas, including oncology, radiation oncology, pain, pathology, imaging, psychological support and the primary disease. In addition, each volume includes a chapter focusing on special populations and the disease's impact / difference on them, and discussion of future directions and quality of life issues. In addition each volume has a chapter written by a private practice oncologist All Current Multidisciplinary Oncology title provide: Consolidation and integration of the varied aspects of multidisciplinary care for major topics in oncology Coverage of all related topic areas, including medical and surgical oncology, radiation oncology, pain, pathology, imaging, psychological support, and the primary disease A chapter focusing on special populations and the disease's impact / difference on them A chapter on community practice written by a private practice oncologist Discussion of quality-of-life issues
  bisphosphonate therapy breast cancer: Breast Disease Adnan Aydiner, Abdullah Igci, Atilla Soran, 2019-07-01 This second updated volume on breast cancer provides a comprehensive overview of its clinical management and current therapies. Updated to reflect the changes in breast cancer staging, the progress in immunotherapy approaches, as well as the latest guidelines for therapies, this book brings readers up to speed with the latest therapeutic regimens in breast cancer and provides an in-depth account of current and new therapeutic approaches. The most important phase III trials, high quality meta-analysis, consensus reports and guidelines are extensively discussed in this new edition and provide the reader with the most up-to-date information. Divided in themed parts, the book examines invasive breast cancer, pre-operative systemic therapy surgical management and recurrence among others, thus providing an in-depth account of breast cancer at the clinical stage. Among the themed parts are a section dedicated to special therapeutic problems, such as breast cancer in older women, Paget’s disease and phyllodes tumors and a section on supportive and follow-up care. By adopting a multidisciplinary approach to breast cancer, this book is a must-have for breast cancer practitioners. With a high number of colored illustrations and edited by highly experienced clinicians, this work enables readers to gain an interdisciplinary perspective on breast diseases. Contributions from an international team of experts present invaluable insight into clinical practice across different settings. Covering both theoretical and practical aspects of breast cancer, this is a highly informative and carefully presented book which will appeal to an international audience of medical, radiation and surgical oncologists.
Osteoporosis treatment: Medications can help - Mayo Clinic
Aug 28, 2024 · The main side effects of bisphosphonate pills are stomach upset and heartburn. Don't lie down or bend over for 30 to 60 minutes to avoid the medicine washing back up into the …

Osteoporosis - Diagnosis and treatment - Mayo Clinic
Feb 24, 2024 · Clinical trials. Explore Mayo Clinic studies testing new treatments, interventions and tests as a means to prevent, detect, treat or manage this condition.

Paget's disease of bone - Diagnosis & treatment - Mayo Clinic
Jan 11, 2023 · Rarely, bisphosphonate therapy has been linked to severe muscle, joint or bone pain, which might not resolve when the medication is discontinued. Bisphosphonates can also increase …

Zoledronic acid (intravenous route) - Mayo Clinic
Apr 1, 2025 · Your doctor will need to know if you have a history of problems with your mouth or teeth (eg, gum disease). Make sure your doctor knows if you have been treated with a …

Tratamiento de la osteoporosis: los medicamentos pueden ayudar
Mar 7, 2025 · Alendronato (Fosamax), una píldora semanal. Risedronato (Actonel, Atelvia), una píldora semanal o mensual. Ibandronato, una píldora mensual o una infusión intravenosa …

Psoriatic arthritis - Diagnosis & treatment - Mayo Clinic
Oct 2, 2021 · Medications. Drugs used to treat psoriatic arthritis include: NSAIDs. Nonsteroidal anti-inflammatory drugs (NSAIDs) can relieve pain and reduce inflammation for people with mild …

Creatinine test - Mayo Clinic
4 days ago · Why it's done. Your healthcare professional may order a creatinine test for the following reasons: To find out if kidney disease is the cause of symptoms you've been having.

Avascular necrosis (osteonecrosis) - Symptoms & causes - Mayo …
May 17, 2022 · Bisphosphonate use. Long-term use of medications to increase bone density might contribute to developing osteonecrosis of the jaw. This rare complication has occurred in some …

Adjuvant bisphosphonate use in patients with early stage …
women with breast cancer [5]. Similarly, data obtained from Cancer Care Ontario (14/April/2020, personal com-munication Fatuma for the Data Disclosure Team, CCO) shows that only about …

Analysis of Effect of Bisphosphonate for Radionuclide Uptake …
with breast (8) and prostate cancer (6) and lung cancer (1). (Table 4.3) Table 4.4 shows the frequency of ... bisphosphonate therapy in cancer patients: the data were analyzed by …

Validation of the PREDICT Breast Version 3.0 Prognostic …
Oct 29, 2024 · Breast cancer is the most common type of cancer diagnosed among women worldwide, with around 2.3 million new cases diagnosed in 2022 1. It also has the highest …

Malignant Hypercalcaemia Management - Gloucestershire …
Though it is commonest in non-small cell lung cancer, breast cancer, multiple myeloma, squamous cell cancers of head and neck and urothelial cancers it can occur in association …

FEATURE ARTICLE Advances in Supportive Care of …
than breast cancer (Small, Smith, Seaman, & Kowalski, in press). The approval of the new generation, nitrogen-containing bis-phosphonate zoledronic acid (Zometa®, No-vartis …

Study shows that selection of breast cancer patients for …
adjuvant bisphosphonate therapy based on Inbiomotion’s ... breast cancer patients compared with current clinical practice ”, said Prof. Roger Gomis, ICREA Research Professor at IRB …

Dental implants in breast cancer patients receiving …
Dec 14, 2023 · Dental implants in breast cancer patients receiving bisphosphonate therapy Mai Ashraf Talaat 1* 1Faculty of Dentistry, October University for Modern Sciences and Arts, 6th of …

Zoledronic Acid and Ibandronic Acid for Adjuvant Treatment …
early breast cancer (the Early Breast Cancer Trialists' Collaborative Group [EBCTCG] meta-analysis 2015) has shown that at 10 years the absolute reductions in the risk of breast cancer …

Early and locally advanced breast cancer: diagnosis and …
invasive breast cancer who have only micrometastases in their sentinel lymph nodes.[2018] 1.4.10 Do not offer further axillary treatment after primary surgery to people with invasive breast …

American Society of Clinical Oncology Executive Summary of …
Bone-modifying agent therapy is only recommended for patients with breast cancer with evidence of bone metastases; denosumab 120 mg subcutaneously every 4 weeks, intravenous pamidro …

The incidence and relative risk of adverse events in patients …
bisphosphonate therapy for breast cancer remains poorly defined. Methods: A literature search was conducted using the PubMed, EMBASE, Cochrane and Web of Science libraries. Risk …

DRUG NAME: Pamidronate - BC Cancer
In the treatment of osteolytic bone metastases in breast cancer and multiple myeloma, pamidronate helps ... such as bisphosphonate therapy. Osteonecrosis of other anatomical …

Study shows that selection of breast cancer patients for …
adjuvant bisphosphonate therapy based on Inbiomotion’s ... breast cancer patients compared with current clinical practice ”, said Prof. Roger Gomis, ICREA Research Professor at IRB …

Adjuvant bisphosphonate service (ABS) in the treatment of …
adjuvant bisphosphonate service (ABS) and have chosen to start bisphosphonate treatment for your early breast cancer. The ABS provides treatment in early breast cancer that may reduce …

Bevacizumab and osteonecrosis of the jaw: incidence and
gastrointestinal cancer, or renal cell cancer are at higher risk of gastrointestinal perforation than those with breast cancer [4, 5]. Of particular relevance to the breast cancer setting, a possible …

Bisphosphonates and Osteonecrosis of the Jaw - BC Cancer
Success of bisphosphonate therapy in cancer treatment has been extensively documented, showing a definite reduction in morbidity in the three million cancer ... Lymphoma/Myeloma …

Tumour-profiling tests to guide adjuvant-bisphosphonate …
breast cancer) may be eligible for adjuvant treatment with bisphosphonates in early breast cancer, including non-post-menopausal patients currently not recommend in clinical guidelines. MAF …

Real‐world data of renal safety of abemaciclib combined with ...
Conclusion: This study shows that abemaciclib combined with bisphosphonate would be safe for renal function in HR+/HER2 ABC patients with bone metastases. KEYWORDS abemaciclib, …

Effects of de-escalated bisphosphonate therapy on bone …
Keywords: Bisphosphonate; Bone metastasis; Breast cancer; Biomarker; Skeletal related event; De-escalated therapy Introduction Bone is the most common site of metastasis in breast …

Bisphosphonates and risk of cancers: a systematic review …
lung (TBL) cancer (2.2 million incident cases), breast cancer (2.0 million incident cases) and colore ctal cancer (1.8 million incident cases). 2 In terms of women, breast cancer was the …

nhs.predict: Breast Cancer Survival and Therapy Benefits
Title Breast Cancer Survival and Therapy Benefits Version 1.4.0 Author Giovanni Tramonti Maintainer Giovanni Tramonti Description Calculate Overall …

Bevacizumab and osteonecrosis of the jaw: incidence and …
cizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Research and …

Open Access Full Text Article Decreased risk of breast …
Breast Cancer: Targets and Therapy 2012:4 75–81 Breast Cancer: Targets and Therapy Decreased risk of breast cancer associated with oral bisphosphonate therapy Aju Mathew1 …

The incidence and relative risk of adverse events in patients …
bisphosphonate therapy for breast cancer remains poorly defined. Methods: A literature search was conducted using the PubMed, EMBASE, Cochrane and Web of Science libraries. Risk …

Managing Bone Health in Breast Cancer - Endocrine
Dec 10, 2022 · bisphosphonate denosumab estrogen abstract Objective: Osteoporosis is a common condition that can be caused or exacerbated by estrogen ... negative effects of …

Bisphosphonate treatment and radiotherapy in metastatic …
effects of radiotherapy and bisphosphonate therapy, and ... Bisphosphonates Combination therapy Introduction Breast cancer is a common invasive cancer that affects more than a …

LETROZOLE - Breast Cancer Now
Breast cancer that has come back or spread Letrozole can also be used to treat people who have: • Local recurrence – breast cancer that has come back in the chest/breast area or in the skin …

Prolia®, Xgeva® (denosumab) - Alaska Department of …
treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. APPROVAL CRITERIA1,2,3,4,5,6,7,8,9 Prolia® 1. Patient is 18 years of age or older AND; 2. Patient has …

Zoledronic Acid: A New Parenteral Bisphosphonate - Clinical …
The value of bisphosphonate therapy for patients who experience complications of advanced cancer (eg, hypercalcemia, metastatic bone disease) is well recog- ... tures and the need for …

Adjuvant Bisphosphonate Therapy in Postmenopausal …
therapy [14]. As soon as breast cancer cells metastasize to the bone, they start to produce factors that cause changes in normal bone remodeling. This leads to a vicious ... that the adjuvant use …

Incidence of Bisphosphonate-associated Osteonecrosis of …
static breast cancer and bisphosphonate therapy were reviewed. All patients were contacted, and missing data were completed through structured interviews with their dentists and physicians …

For the Patient: Bisphosphonates and Oral Health in ... - BC …
The pre-bisphosphonate dental appointments should establish a dentition that the patient can maintain for the rest of their life. Informed consent should be obtained, with a signed patient …

Zoledronic acid: Zometa®; Reclast® - OHSU
Mar 31, 2023 · receiving therapy and serum creatinine must be assessed prior to retreatment. Prevention of aromatase inhibitor-induced bone loss in breast cancer 4 mg IV every 6 months …

Bisphosphonates for treatment of osteoporosis
patients who have persisted with bisphosphonate therapy for 3 to 5 years and for those at low risk of fracture. • High-risk patients with osteoporotic bone mineral density ... in a clinical trial …

Denosumab (Prolia® & Xgeva®) (for Louisiana Only)
receiving adjuvant aromatase inhibitor therapy for breast cancer in patients who meet all of the following criteria : • Initial Therapy . o Diagnosis of breast cancer; and . o Patient is receiving …

Altered Calcium Metabolism in Patients on Long-term …
Key Words: Breast neoplasms, bone neoplasms, diphosphonates, hyperparathyroidism, secondary, calcium. ANTICANCER RESEARCH 29: 2707-2712 (2009) Altered Calcium …

Can patients with a history of radiation therapy use FORTEO ...
Aug 16, 2022 · o radiation therapy for a soft tissue malignancy, such as breast cancer (such patients likely have experienced radiation affecting the skeleton around the breast [the …

Adjuvant bisphosphonate - leaflets.ekhuft.nhs.uk
often many years after patients have had an operation to remove the cancer from their breast. Doctors think this could be because the chemicals that control bone turnover could also …

Adjuvant Bisphosphonate Therapy in Postmenopausal …
therapy [14]. As soon as breast cancer cells metastasize to the bone, they start to produce factors that cause changes in normal bone remodeling. This leads to a vicious ... that the adjuvant use …

BC Cancer Protocol Summary for Adjuvant Therapy for …
Bisphosphonate therapy recommended to begin within 1 year of diagnosis and should start no later than 18 months of definitive breast cancer surgery ; ... five years in early breast cancer …

North of Scotland Clinical Management Guideline (CMG): …
Lead Group: NCA Breast Cancer Clinical Management Guideline Review Group File Reference: NCA-CMG-BRE19 Approved: June 28th, 2019 Published: ... HER2 targeted therapy +/- …

Medicine Guideline - Zoledronic Acid for early / locally …
2. Hadji et al Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of Oncology 2016;27(3):379. 3. Early Breast Cancer …

Bisphosphonate induced osteonecrosis of jaw in breast …
Background: Bisphosphonate therapy is widely used for the treatment of ... Key words: Bisphosphonate, breast, cancer, osteonecrosis Access this article online Quick Response Code:

Dental implants in breast cancer patients receiving …
This review article aims to assess the success of dental implants in breast cancer patients receiving bisphosphonate therapy, and to evaluate the risk of developing bisphosphonate …

Adjuvant bisphosphonate treatment for breast cancer: Why …
optimism regarding adjuvant bisphosphonate therapy, results from large trials are conflicting. Further investigation into factors influencing response to bisphosphonate treat-ment or …

The adverse effects of bisphosphonates in breast cancer: A …
potential benefits in a clear way through websites such as Predict:Breast Cancer (breast.pre-dict.nhs.uk), but rather remarkably the potential harms have not been quantified in the same …

Prevention of bone metastases from breast cancer by …
Breast Cancer Vol. 10 No. 1 January 2003 Review Article Prevention of Bone Metastases from Breast Cancer by Adjuvant Bisphosphonate Therapy Norio Kohno *~ and Ikuo Kokufu .2 * …

Open Access Full Text Article Decreased risk of breast …
Breast Cancer: Targets and Therapy 2012:4 75–81 Breast Cancer: Targets and Therapy Decreased risk of breast cancer associated with oral bisphosphonate therapy Aju Mathew1 …

Adjuvant Therapy of Breast Cancer – Bisphosphonates
Adjuvant Therapy of Breast Cancer – Bisphosphonates Tiina Saarto The skeleton is a first site of recurrence in every third relapse in breast cancer. Approximately 70% (50–80%) of metastatic …

Osteonecrosis of the Maxilla and Mandible in Patients with …
gating bisphosphonate therapy have demonstrated a de-crease in the risk for an SRE by approximately one third. Hence, bisphosphonate therapy has been incorporated into the …